18F-FDG PET/CT半定量参数与IASLC/ATS/ERS肺腺癌分类的关系
这项回顾性研究纳入419例IA-IIIA期肺腺癌患者,分析术前PET/CT半定量参数(SUVmax、BSV、BSL)与IASLC/ATS/ERS组织学亚型、Ki67增殖活性及EGFR/ALK突变状态的关系。结果显示侵袭性腺癌参数显著高于微浸润腺癌,微浸润腺癌高于原位腺癌;SUVmax 0.90和BSL 3.62是区分微浸润腺癌与原位腺癌的最佳阈值,表现为纯磨玻璃结节时敏感度和特异度均为100%。代谢体积参数区分生长方式优于SUVmax,SUVmax和BSL与多数亚型Ki67相关,但PET/CT参数与EGFR/ALK突变状态无相关性。
要点
- 侵袭性腺癌SUVmax、BSV、BSL显著高于微浸润腺癌,微浸润腺癌高于原位腺癌(均p<0.05)。
- 区分微浸润腺癌与原位腺癌的最佳阈值为SUVmax 0.90和BSL 3.62,纯磨玻璃结节中敏感度和特异度均100%。
- 区分生长方式时,BSV和BSL较SUVmax是更好的潜在独立因素。
核心结论
- 术前PET/CT半定量参数可作为无创替代指标提示IASLC/ATS/ERS亚型和Ki67指数,可能有助于改进精准手术和术后辅助治疗的管理。
研究设计与样本
- 回顾性研究,纳入419例(男150例,女269例;中位年龄59.0岁,范围23.0-84.0岁)经手术切除的IA-IIIA期肺腺癌患者,均有术前肺肿瘤PET/CT数据。
关键影像表现/征象
- 侵袭性腺癌的SUVmax、BSV、BSL值显著高于微浸润腺癌,微浸润腺癌高于原位腺癌(均p<0.05)。
- 区分微浸润腺癌与原位腺癌的最佳阈值为SUVmax 0.90和BSL 3.62,表现为纯磨玻璃结节时敏感度和特异度均为100%。
- 代谢体积参数(BSV和BSL)在区分生长方式方面较代谢参数(SUVmax)是更好的潜在独立因素。
- 除微乳头型和实性为主型组外,大多数亚型中SUVmax和BSL与Ki67呈强或中度相关,而BSV与Ki67无此相关。
- PET/CT参数与EGFR/ALK突变状态无相关性。
诊断标准与关键数值
- 区分微浸润腺癌与原位腺癌:SUVmax最佳阈值0.90,BSL最佳阈值3.62,表现为纯磨玻璃结节时敏感度100%、特异度100%。
- 亚型比较采用Mann-Whitney U检验或Kruskal-Wallis检验,最佳阈值采用受试者工作特征曲线分析,相关性采用Spearman相关分析,统计学显著性设为p<0.05。
临床应用与阅片要点
- 术前PET/CT半定量参数(SUVmax、BSV、BSL)可无创提示IASLC/ATS/ERS亚型和Ki67指数。
- 区分生长方式时BSV和BSL较SUVmax是更好的潜在独立因素。
- 纯磨玻璃结节中SUVmax 0.90和BSL 3.62可用于区分微浸润腺癌与原位腺癌。
- SUVmax和BSL与大多数亚型Ki67相关,但微乳头型和实性为主型组除外。
- PET/CT参数与EGFR/ALK突变状态无相关性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To investigate the relationship between 18F-FDG PET/CT semi-quantitative parameters and the International Association for the Study of Lung Cancer, American Thoracic Society/European Respiratory Society (IASLC/ATS/ERS) histopathologic classification, including histological subtypes, proliferation activity, and somatic mutations.
MATERIALS AND METHODS: This retrospective study included 419 patients (150 males, 269 females; median age, 59.0 years; age range, 23.0-84.0 years) who had undergone surgical removal of stage IA-IIIA lung adenocarcinoma and had preoperative PET/CT data of lung tumors. The maximum standardized uptake values (SUVmax), background-subtracted volume (BSV), and background-subtracted lesion activity (BSL) derived from PET/CT were measured. The IASLC/ATS/ERS subtypes, Ki67 score, and epidermal growth factor/anaplastic lymphoma kinase (EGFR/ALK) mutation status were evaluated. The PET/CT semi-quantitative parameters were compared between the tumor subtypes using the Mann-Whitney U test or the Kruskal-Wallis test. The optimum cutoff values of the PET/CT semi-quantitative parameters for distinguishing the IASLC/ATS/ERS subtypes were calculated using receiver operating characteristic curve analysis. The correlation between the PET/CT semi-quantitative parameters and pathological parameters was analyzed using Spearman's correlation. Statistical significance was set at p < 0.05.
RESULTS: SUVmax, BSV, and BSL values were significantly higher in invasive adenocarcinoma (IA) than in minimally IA (MIA), and the values were higher in MIA than in adenocarcinoma in situ (AIS) (all p < 0.05). Remarkably, an SUVmax of 0.90 and a BSL of 3.62 were shown to be the optimal cutoff values for differentiating MIA from AIS, manifesting as pure ground-glass nodules with 100% sensitivity and specificity. Metabolic-volumetric parameters (BSV and BSL) were better potential independent factors than metabolic parameters (SUVmax) in differentiating growth patterns. SUVmax and BSL, rather than BSV, were strongly or moderately correlated with Ki67 in most subtypes, except for the micropapillary and solid predominant groups. PET/CT parameters were not correlated with EGFR/ALK mutation status.
CONCLUSION: As noninvasive surrogates, preoperative PET/CT semi-quantitative parameters could imply IASLC/ATS/ERS subtypes and Ki67 index and thus may contribute to improved management of precise surgery and postoperative adjuvant therapy.
引用
- Bu L, Tu N, Wang K, et al. Relationship between 18F-FDG PET/CT Semi-Quantitative Parameters and International Association for the Study of Lung Cancer, American Thoracic Society/European Respiratory Society Classification in Lung Adenocarcinomas. Korean J Radiol. 2022. PMID: 34983098. doi:10.3348/kjr.2021.0455
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。